Company news: Lilly and Amgen

Share this article:
Greater marketing and sales costs hurt Lilly's third-quarter profits, which slipped 6% to $1.2 billion. The company said sales rose 20% or more for several products during the quarter, including Cymbalta, Humalog, Strattera and Forteo, along with animal health products, but was hit by costs associated with healthcare reform, which reduced revenue by around $330 million and increased administrative expenses by around $135 million for the first nine months of the year.

Amgen is laying off 380 employees from its R&D division, Bloomberg reported, after slashing research spending 26% during the second quarter to accommodate the expense associated with moving three pipeline candidates into larger clinical trials.
Share this article:

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.